Ma S - Search Results

1

YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8⁺ T cells.

Ma S, Sun B, Duan S, Han J, Barr T, Zhang J, Bissonnette MB, Kortylewski M, He C, Chen J, Caligiuri MA, Yu J. Ma S, et al. Nat Immunol. 2023 Feb;24(2):255-266. doi: 10.1038/s41590-022-01398-6. Epub 2023 Jan 19. Nat Immunol. 2023. PMID: 36658237 Free PMC article.

2

Inhibition of Acute Graft-versus-Host Disease with Retention of Graft-versus-Tumor Effects by Dimethyl Fumarate.

Han J, Ma S, Gong H, Liu S, Lei L, Hu B, Xu Y, Liu H, Wu D. Han J, et al. Among authors: ma s. Front Immunol. 2017 Nov 20;8:1605. doi: 10.3389/fimmu.2017.01605. eCollection 2017. Front Immunol. 2017. PMID: 29209333 Free PMC article.

3

The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.

Dong W, Wu X, Ma S, Wang Y, Nalin AP, Zhu Z, Zhang J, Benson DM, He K, Caligiuri MA, Yu J. Dong W, et al. Among authors: ma s. Cancer Discov. 2019 Oct;9(10):1422-1437. doi: 10.1158/2159-8290.CD-18-1259. Epub 2019 Jul 24. Cancer Discov. 2019. PMID: 31340937 Free PMC article.

4

An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.

Ma R, Lu T, Li Z, Teng KY, Mansour AG, Yu M, Tian L, Xu B, Ma S, Zhang J, Barr T, Peng Y, Caligiuri MA, Yu J. Ma R, et al. Among authors: ma s. Cancer Res. 2021 Jul 1;81(13):3635-3648. doi: 10.1158/0008-5472.CAN-21-0035. Epub 2021 May 18. Cancer Res. 2021. PMID: 34006525 Free PMC article.

5

Dual roles of a novel oncolytic viral vector-based SARS-CoV-2 vaccine: preventing COVID-19 and treating tumor progression.

Sun Y, Dong W, Tian L, Rao Y, Qin C, Jaramillo SA, Settles EW, Ma S, Zhang J, Yu K, Xu B, Yan J, Ma R, Li Z, Dadwal SS, Barker BM, Keim PS, Feng P, Caligiuri MA, Yu J. Sun Y, et al. Among authors: ma r, ma s. bioRxiv [Preprint]. 2021 Jun 7:2021.06.07.447286. doi: 10.1101/2021.06.07.447286. bioRxiv. 2021. PMID: 34127971 Free PMC article. Preprint.

6

The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity.

Ma S, Yan J, Barr T, Zhang J, Chen Z, Wang LS, Sun JC, Chen J, Caligiuri MA, Yu J. Ma S, et al. J Exp Med. 2021 Aug 2;218(8):e20210279. doi: 10.1084/jem.20210279. Epub 2021 Jun 23. J Exp Med. 2021. PMID: 34160549 Free PMC article.

7

Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer.

Teng KY, Mansour AG, Zhu Z, Li Z, Tian L, Ma S, Xu B, Lu T, Chen H, Hou D, Zhang J, Priceman SJ, Caligiuri MA, Yu J. Teng KY, et al. Among authors: ma s. Gastroenterology. 2022 Apr;162(4):1319-1333. doi: 10.1053/j.gastro.2021.12.281. Epub 2022 Jan 6. Gastroenterology. 2022. PMID: 34999097 Free PMC article.

8

PDGF-D-PDGFRβ signaling enhances IL-15-mediated human natural killer cell survival.

Ma S, Tang T, Wu X, Mansour AG, Lu T, Zhang J, Wang LS, Caligiuri MA, Yu J. Ma S, et al. Proc Natl Acad Sci U S A. 2022 Jan 18;119(3):e2114134119. doi: 10.1073/pnas.2114134119. Proc Natl Acad Sci U S A. 2022. PMID: 35027451 Free PMC article.

9

Targeting the RNA m⁶A modification for cancer immunotherapy.

Li X, Ma S, Deng Y, Yi P, Yu J. Li X, et al. Among authors: ma s. Mol Cancer. 2022 Mar 16;21(1):76. doi: 10.1186/s12943-022-01558-0. Mol Cancer. 2022. PMID: 35296338 Free PMC article. Review.

10

A four-stage model for murine natural killer cell development in vivo.

Ma S, Caligiuri MA, Yu J. Ma S, et al. J Hematol Oncol. 2022 Mar 21;15(1):31. doi: 10.1186/s13045-022-01243-1. J Hematol Oncol. 2022. PMID: 35313938 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,492 results

Search Page

Filters